News

14 November 2019

New grant for membrane protein stabilization chemistry

CALIXAR, the French biotech company specialized in the native isolation of membrane therapeutic targets/antigens and the French University of Avignon – Bio-organic Chemistry and Amphiphilic Systems Team (CBSA) – announce new grant approval for the CHEM2STAB common laboratory (CHEMistry for STABilization) from the French National Research Agency (ANR).

view details

24 October 2019

New vaccine formulation against influenza infection

Calixar announces the publication of a new article in Vaccine by Calixar in collaboration with the VirPath laboratory (Lyon) and International infectious diseases Research Center, Quebec (Laval University). This publication describes an improved process to formulate the influenza vaccine since it allows the same protection in animals and neutralizing antibody responses but with 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip® or Fluviral®.

view details

15 October 2019

Novel influenza vaccine : Calixar patent granted in Europe

After the United States Patent Office in last June, CALIXAR announces the grant of its patent by the European Patent Office concerning the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (EP3194433). This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.

view details

23 September 2019

New publication on Calixar's stabilization expertise for native MPs

Calixar announces the publication of a new article by Calixar in collaboration with Roche Pharmaceuticals and The University of Basel (Biozentrum) in Scientific Reports.

view details

6 September 2019

Novel innovative detergent family for MP extraction and stabilization

CALIXAR announces the publication of a new article in the framework of the CHEM2STAB common laboratory.

view details

4 September 2019

Calixar novel patent publication

CALIXAR announces the official grant of its patent by the European Patent Office

view details

26 August 2019

New publications on MRP4 solubilization and stabilization

CALIXAR announces the publication of new studies on MRP4 solubilization and stabilization in collaboration with Aston University.

view details

17 June 2019

Calixar and VirPath patent granted in the United States

CALIXAR announces the grant of its patent by the United States Patent and Trademark Office for the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (US 10144917 B2).

view details

29 May 2019

New glycosylated calixarene-based detergent for MP stabilization

CALIXAR announces the publication of a new article in collaboration with Gregory Durand’s laboratory.

view details

15 May 2019

MemTrain EU-Cofund Award

CALIXAR is proud to announce the grant of the EU Marie Sklodowska-Curie funded COFUND Doctoral Programme entitled MemTrain.

view details